CHINARES PHARMA (03320) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of 269.574 billion yuan, representing a year-on-year increase of 4.62%. Profit attributable to shareholders was 4.045 billion yuan, up 20.73% compared to the previous year. Earnings per share were 0.64 yuan, and a final dividend of 0.122 yuan was declared.
In 2025, the Group actively supported national strategies, focused on cultivating new quality productive forces in the pharmaceutical sector, and prioritized the development of strategic emerging industries. It implemented multiple measures to drive R&D innovation, strengthened external mergers and acquisitions as well as product introductions, enhanced supply chain resilience and security, and advanced its digital transformation and green, low-carbon development initiatives.
Against a backdrop of intensified competition and significant downward pressure in the pharmaceutical industry, the Group achieved growth in both revenue and profit in 2025. During the "14th Five-Year Plan" period, its revenue growth rate exceeded the industry average. The Group maintains a leading comprehensive influence within China's pharmaceutical sector, operating as an integrated leader with strengths in both manufacturing and distribution. Its overall operational scale ranks third in the industry, its pharmaceutical manufacturing business holds the second position among the top 100 pharmaceutical industrial enterprises, and its pharmaceutical distribution business ranks third in terms of scale.
During the reporting period, the Group's brands received notable honors. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. ("CR Sanjiu") was awarded the first prize in the National Ministry of Education's Outstanding Scientific Research Achievements and received the highest "Benchmark" rating in the State-owned Assets Supervision and Administration Commission's "Sci-Tech Reform Initiative" for three consecutive years. Brands "Jiangzhong" and "Dong-E-E-Jiao" were included in the first batch of China's Famous Consumer Products list by the Ministry of Industry and Information Technology ("MIIT"). An enterprise under China Resources Double-Crane Pharmaceutical Co., Ltd. ("CR Double-Crane") was recognized as a "National Excellent Case in Healthy Enterprise Construction." Furthermore, CR Sanjiu, CR Double-Crane, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. ("CR Jiangzhong"), and Dong-E-E-Jiao Co., Ltd. ("Dong-E-E-Jiao") were jointly selected for the MIIT's "Outstanding Smart Factory" list, demonstrating the Group's multi-level and multi-dimensional brand influence.